Gabapentin Tablet
Product Images NDC 76420-497

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 76420-497). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin-800mg (Gabapentin 800mg)

Labels for Gabapentin Tablets, USP 800 mg by Enovachem Pharmaceuticals, packaged in various quantities including 30, 60, 90, 100, 120, 240, and 500 tablets. The labels include NDC numbers, manufacturer ScieGen Pharmaceuticals, Inc., batch and lot information, storage instructions, and a barcode. Each label bears caution about prescription-only dispensing.*

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain scores over an 8-week period comparing placebo and gabapentin 3600 mg/day. The horizontal axis represents weeks, and the vertical axis represents mean pain scores from 0 to 10. The graph includes annotations for a 4-week dose titration period followed by a 4-week fixed dose period. Gabapentin shows a decreasing trend in mean pain scores, while placebo remains relatively stable.*

FDA Label Image

Figure 2 (Image 02)

A line graph displaying mean pain scores over a 7-week period from baseline, comparing placebo and Gabapentin at doses of 1800 mg/day and 2400 mg/day. The x-axis represents weeks, and the y-axis shows mean pain scores. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 3 (Image 03)

A bar chart showing the proportion of responders (patients with at least 50% reduction in pain score) at endpoint in two controlled postherpetic neuralgia (PHN) studies. The chart compares placebo groups (PBO) with Gabapentin (GBP) at specified doses, showing higher responder percentages in Gabapentin groups for both studies. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Image-04 (Image 04)

A formula representing the creatinine clearance calculation (CLCr) is shown, which involves age, weight, serum creatinine, and an adjustment factor for female patients. This text panel depicts a clinical pharmacokinetic calculation relevant to drug dosing considerations.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin showing a cyclohexane ring attached to a central carbon bonded to an amino group and a carboxymethyl group.*

FDA Label Image

Image-09 (Image 09)

A scatter plot chart depicting percentage differences on the vertical axis against daily doses in milligrams on the horizontal axis. It compares results from three studies labeled as Study a, Study b, and Study c across four daily dose levels: 600 mg, 900 mg, 1200 mg, and 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.